Cited by 442CRISPR and Genetic EngineeringVirus-based gene therapy researchCAR-T cell therapy research

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors

Wang, Xiaoling, Wang, Yebo, Wu, Xiwei, Wang, Jinhui, Wang, Yingjia, Qiu, Zhaojun, Chang, Tammy, Huang, He, Lin, Ren-Jang, Yee, Jiing-Kuan·2015·Nature Biotechnology

DOI 10.1038/nbt.3127

Open this paper in CoChat — free account

Abstract

The utility of CRISPR-Cas9 and TALENs for genome editing may be compromised by their off-target activity. We show that integrase-defective lentiviral vectors (IDLVs) can detect such off-target cleavage with a frequency as low as 1%. In the case of Cas9, we find frequent off-target sites with a one-base bulge or up to 13 mismatches between the single guide RNA (sgRNA) and its genomic target, which refines sgRNA design.

Integrity signals

Registry

Crossref · 10.1038/nbt.3127

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citation
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
PEAR: a fast and accurate Illumina Paired-End reAd mergeR
Zhang, J., Kobert, K., Flouri, T., & Stamatakis, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt593 · Cited by 4,497
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487

Flagged first, then by citations

Show all 20 references

Sorted by citations

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR
Haeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1012-2 · Cited by 1,756
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273
Self-citation
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering
Labun, K., Montague, T. G., Gagnon, J. A., Thyme, S. B., & Valen, E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw398 · Cited by 954
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy
Long, C., Amoasii, L., Mireault, A. A., McAnally, J., Li, H. Z., Sanchez‐Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel‐Duby, R., & Olson, E. N. (2015) · Science · doi:10.1126/science.aad5725 · Cited by 973
Enhanced Rice Blast Resistance by CRISPR/Cas9-Targeted Mutagenesis of the ERF Transcription Factor Gene OsERF922
Wang, F., Wang, C., Liu, P., Lei, C., Hao, W., Gao, Y., Liu, Y., & Zhao, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154027 · Cited by 849
Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells
Kim, D., Kim, J., Hur, J. K., Been, K. W., Yoon, S.-H., & Kim, J.-S. (2016) · Nature Biotechnology · doi:10.1038/nbt.3609 · Cited by 731
Genome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 736
DeepCRISPR: Optimized CRISPR guide RNA design by deep learning
Chuai, G., Ma, H., Yan, J., Chen, M., Hong, N., Xue, D., Zhou, C., Zhu, C., Chen, K., Duan, B., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1459-4 · Cited by 641
Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells
Kleinstiver, B. P., Tsai, S. Q., Prew, M. S., Nguyen, N. T., Welch, M. M., Lopez, J. M., McCaw, Z. R., Aryee, M. J., & Joung, J. K. (2016) · Nature Biotechnology · doi:10.1038/nbt.3620 · Cited by 670
Off-target effects in CRISPR/Cas9 gene editing
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1143157 · Cited by 704
“IDLV was first designed to detect DSBs created by ZFNs and TALENs (Gabriel et al., 2011; Wang et al., 2015; Wang et al., 2021).”
BackgroundInfluential
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Induced Pluripotent Stem Cells Meet Genome Editing
Hockemeyer, D., & Jaenisch, R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.013 · Cited by 499
“While these data argue for the high specificity of Cas9, data in cancer cells suggest that offtargets can be frequently detected (Frock et al., 2015; Fu et al., 2014; Tsai et al., 2015; Wang et al., 2015b).”
Background
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases
Tsai, S. Q., & Joung, J. K. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.28 · Cited by 523
Mapping the genomic landscape of CRISPR-Cas9 cleavage
Cameron, P., Fuller, C. K., Donohoue, P. D., Jones, B. N., Thompson, M. S., Carter, M. M., Gradia, S., Vidal, B., Garner, E., Slorach, E. M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4284 · Cited by 443
Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457
DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Xue, C., & Greene, E. C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.02.008 · Cited by 431
BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks
Yan, W. X., Mirzazadeh, R., Garnerone, S., Scott, D., Schneider, M. W., Kallas, T., Custodio, J., Wernersson, E., Li, Y., Gao, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15058 · Cited by 369
CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off‐Target Evaluation, and Strategies to Mitigate Off‐Target Effects
Manghwar, H., Li, B., Ding, X., Hussain, A., Lindsey, K., Zhang, X., & Jin, S. (2020) · Advanced Science · doi:10.1002/advs.201902312 · Cited by 347
Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs
Listgarten, J., Weinstein, M., Kleinstiver, B. P., Sousa, A. A., Joung, J. K., Crawford, J., Gao, K., Hoang, L., Elibol, M., Doench, J. G., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0178-6 · Cited by 336
Origins of Programmable Nucleases for Genome Engineering
Chandrasegaran, S., & Carroll, D. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.014 · Cited by 344
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Akçakaya, P., Bobbin, M. L., Guo, J. A., Malagon-Lopez, J., Clement, K., Garcia, S. P., Fellows, M. D., Porritt, M. J., Firth, M. A., Carreras, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0500-9 · Cited by 324
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity
Tycko, J., Myer, V. E., & Hsu, P. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.07.004 · Cited by 315
Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9
Park, C., Kim, D. H., Sung, J. J., Sung, J. J., Lee, J., Bae, S., Kim, D., Kim, D., & Kim, J. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.07.001 · Cited by 305
Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice
Aida, T., Chiyo, K., Usami, T., Ishikubo, H., Imahashi, R., Wada, Y., Tanaka, K. F., Sakuma, T., Yamamoto, T., & Tanaka, K. (2015) · Genome biology · doi:10.1186/s13059-015-0653-x · Cited by 298
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 310
CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity
Lazzarotto, C. R., Malinin, N. L., Li, Y., Zhang, R., Yang, Y., Lee, G., Cowley, E., He, Y., Lan, X., Jividen, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0555-7 · Cited by 294
Genome-wide target specificities of CRISPR RNA-guided programmable deaminases
Kim, D., Lim, K., Kim, S., Yoon, S.-H., Kim, K., Ryu, S.-M., & Kim, J. (2017) · Nature Biotechnology · doi:10.1038/nbt.3852 · Cited by 281
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
CRISPR-Cas9 for cancer therapy: Opportunities and challenges
Chen, M., Mao, A., Xu, M., Weng, Q., Mao, J., & Ji, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.017 · Cited by 272
Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing
Miyaoka, Y., Berman, J. R., Cooper, S., Mayerl, S. J., Chan, A. H., Zhang, B., Karlin-Neumann, G. A., & Conklin, B. R. (2016) · Scientific Reports · doi:10.1038/srep23549 · Cited by 277
Detecting DNA double-stranded breaks in mammalian genomes by linear amplification–mediated high-throughput genome-wide translocation sequencing
Hu, J., Meyers, R. M., Dong, J., Panchakshari, R. A., Alt, F. W., & Frock, R. L. (2016) · Nature Protocols · doi:10.1038/nprot.2016.043 · Cited by 274
Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9
Singh, D., Sternberg, S. H., Fei, J., Doudna, J. A., & Ha, T. (2016) · Nature Communications · doi:10.1038/ncomms12778 · Cited by 269
Partial DNA-guided Cas9 enables genome editing with reduced off-target activity
Yin, H., Song, C.-Q., Suresh, S., Kwan, S.-Y., Wu, Q., Walsh, S., Ding, J., Bogorad, R. L., Zhu, L. J., Wolfe, S. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2559 · Cited by 240
Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing
Swarts, D. C., & Jinek, M. (2018) · WIREs RNA · doi:10.1002/wrna.1481 · Cited by 267
Potential pitfalls of CRISPR/Cas9‐mediated genome editing
Peng, R., Lin, G., & Li, J. (2016) · The FEBS Journal · doi:10.1111/febs.13586 · Cited by 213
The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells
Lee, C. M., Cradick, T. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.8 · Cited by 250
Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020) · Plant Biotechnology Journal · doi:10.1111/pbi.13383 · Cited by 254
Use of designer nucleases for targeted gene and genome editing in plants
Weeks, D. P., Spalding, M. H., & Yang, B. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12448 · Cited by 231
Cas9-chromatin binding information enables more accurate CRISPR off-target prediction
Singh, R., Kuscu, C., Quinlan, A., Qi, Y., & Adli, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv575 · Cited by 217
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells
Hoban, M. D., Lumaquin, D., Kuo, C. Y., Romero, Z., Long, J., Ho, M., Young, C. S., Mojadidi, M., Fitz-Gibbon, S., Cooper, A. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.148 · Cited by 220
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 232
Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S. (2016) · Genome Research · doi:10.1101/gr.199588.115 · Cited by 208
A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action
Abadi, S., Yan, W. X., Amar, D., & Mayrose, I. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005807 · Cited by 208
A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing
Liu, K. I., Ramli, M. N., Woo, A., Wang, Y., Zhao, T., Zhang, X., Yim, D., Chong, B. Y., Ali, G., Chua, M. Z. H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2179 · Cited by 199
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 200
Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity
Cromwell, C. R., Sung, K., Park, J., Krysler, A. R., Jovel, J., Kim, S. K., & Hubbard, B. P. (2018) · Nature Communications · doi:10.1038/s41467-018-03927-0 · Cited by 190
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 193
CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to enhance genome editing
Chiang, T.-W. W., le Sage, C., Larrieu, D., Demir, M., & Jackson, S. P. (2016) · Scientific Reports · doi:10.1038/srep24356 · Cited by 171
CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters
Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H., & Gorodkin, J. (2018) · Genome biology · doi:10.1186/s13059-018-1534-x · Cited by 174
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
CRISPR/Cas9-mediated genome editing and gene replacement in plants: Transitioning from lab to field
Schaeffer, S. M., & Nakata, P. A. (2015) · Plant Science · doi:10.1016/j.plantsci.2015.09.011 · Cited by 166
Systematic analysis of CRISPR–Cas9 mismatch tolerance reveals low levels of off-target activity
Anderson, E. M., Haupt, A., Schiel, J. A., Chou, E. T., Machado, H. B., Strezoska, Ž., Lenger, S., McClelland, S., Birmingham, A., Vermeulen, A., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.06.427 · Cited by 154
Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs
Xu, P., Tong, Y., Liu, X., Wang, T., Li, C., Wang, B.-Y., Lv, X., Huang, Y., & Liu, D. (2015) · Scientific Reports · doi:10.1038/srep12065 · Cited by 152
Efficient CRISPR-Cas9-Mediated Generation of Knockin Human Pluripotent Stem Cells Lacking Undesired Mutations at the Targeted Locus
Merkle, F. T., Neuhausser, W. M., Santos, D., Valen, E., Gagnon, J. A., Maas, K., Sandoe, J., Schier, A. F., & Eggan, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.007 · Cited by 152
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 150
Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage
Josephs, E. A., Koçak, D. D., Fitzgibbon, C. J., McMenemy, J., Gersbach, C. A., & Marszałek, P. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv892 · Cited by 147
Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration
Burnight, E. R., Gupta, M., Wiley, L. A., Anfinson, K. R., Tran, A. A., Triboulet, R., Hoffmann, J. M., Klaahsen, D., Andorf, J. L., Jiao, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.015 · Cited by 153
The chemistry of Cas9 and its CRISPR colleagues
Chen, J. S., & Doudna, J. A. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0078 · Cited by 143
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage
Kulcsár, P. I., Tálas, A., Huszár, K., Ligeti, Z., Tóth, E., Weinhardt, N., Fodor, E., & Welker, E. (2017) · Genome biology · doi:10.1186/s13059-017-1318-8 · Cited by 134
Computational Tools and Resources for CRISPR/Cas Genome Editing
Li, C., Chu, W., Gill, R. A., Sang, S., Shi, Y., Hu, X., Yang, Y., Zaman, Q. U., & Zhang, B. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.02.006 · Cited by 134
Expanding the Range of CRISPR/Cas9 Genome Editing in Rice
Hu, X., Wang, C., Fu, Y., Liu, Q., Jiao, X., & Wang, K. (2016) · Molecular Plant · doi:10.1016/j.molp.2016.03.003 · Cited by 129
In Silico Meets In Vivo : Towards Computational CRISPR-Based sgRNA Design
Chuai, G., Wang, Q., & Liu, Q. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.06.008 · Cited by 134
Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 133
Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activatorsPreprint
Polstein, L. R., Pérez‐Piñera, P., Koçak, D. D., Vockley, C. M., Bledsoe, P. J., Song, L., Safi, A., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.179044.114 · Cited by 132
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing
Lee, C. M., Cradick, T. J., Fine, E. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.1 · Cited by 123
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 119
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity
Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski‐Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U. C., Grundhoff, A. T., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3467 · Cited by 125
VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
Montagna, C., Petris, G., Casini, A., Maule, G., Franceschini, G. M., Zanella, I., Conti, L., Arnoldi, F., Burrone, O. R., Zentilin, L., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.05.010 · Cited by 117
CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X
Karimova, M., Beschorner, N., Dammermann, W., Chemnitz, J., Indenbirken, D., Bockmann, J., Grundhoff, A. T., Lüth, S., Buchholz, F., Wiesch, J. S. Z., et al. (2015) · Scientific Reports · doi:10.1038/srep13734 · Cited by 116
DNA-binding-domain fusions enhance the targeting range and precision of Cas9
Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M. G., Brodsky, M. H., Zhu, L. J., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3624 · Cited by 117
CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives
Lee, J. S., Grav, L. M., Lewis, N. E., & Faustrup Kildegaard, H. (2015) · Biotechnology Journal · doi:10.1002/biot.201500082 · Cited by 117
Genome editing using FACS enrichment of nuclease-expressing cells and indel detection by amplicon analysis
Lonowski, L. A., Narimatsu, Y., Riaz, A., Delay, C. M., Yang, Z., Niola, F., Duda, K., Ober, E. A., Clausen, H., Wandall, H. H., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2016.165 · Cited by 111
Tools for experimental and computational analyses of off-target editing by programmable nucleases
Bao, X. R., Pan, Y., Lee, C. M., Davis, T. H., & Bao, G. (2021) · Nature Protocols · doi:10.1038/s41596-020-00431-y · Cited by 106
How specific is CRISPR/Cas9 really?
O’Geen, H., Yu, A. S., & Segal, D. J. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.10.001 · Cited by 108
Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery
Bolukbasi, M. F., Gupta, A., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3684 · Cited by 112
CRISPR guide RNA design for research applications
Mohr, S. E., Hu, Y., Ewen‐Campen, B., Housden, B. E., Viswanatha, R., & Perrimon, N. (2016) · FEBS Journal · doi:10.1111/febs.13777 · Cited by 112
Large-scale production of human pluripotent stem cell derived cardiomyocytes
Kempf, H., Andrée, B., & Zweigerdt, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.016 · Cited by 109
Genome editing: the road of CRISPR/Cas9 from bench to clinic
Eid, A., & Mahfouz, M. M. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.111 · Cited by 111
Optimizing genome editing strategy by primer-extension-mediated sequencing
Yin, J., Liu, M., Liu, Y., Wu, J., Gan, T., Zhang, W., Li, Y., Zhou, Y., & Hu, J. (2019) · Cell Discovery · doi:10.1038/s41421-019-0088-8 · Cited by 108
dCas9: A Versatile Tool for Epigenome Editing
Brocken, D. J. W., Tark‐Dame, M., & Dame, R. T. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.015 · Cited by 113
Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering
Guha, T. K., Wai, A., & Hausner, G. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.12.006 · Cited by 117
Modeling Disease In Vivo With CRISPR/Cas9
Dow, L. E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.006 · Cited by 111
Resources for the design of CRISPR gene editing experiments
Graham, D. B., & Root, D. E. (2015) · Genome biology · doi:10.1186/s13059-015-0823-x · Cited by 108
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 108
An overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools
Wang, J., Zhang, X., Cheng, L., & Luo, Y. (2019) · RNA Biology · doi:10.1080/15476286.2019.1669406 · Cited by 106
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03765-1 · Cited by 114
Defining CRISPR–Cas9 genome-wide nuclease activities with CIRCLE-seq
Lazzarotto, C. R., Nguyen, N. T., Tang, X., Malagon-Lopez, J., Guo, J. A., Aryee, M. J., Joung, J. K., & Tsai, S. Q. (2018) · Nature Protocols · doi:10.1038/s41596-018-0055-0 · Cited by 98
Biased and unbiased methods for the detection of off-target cleavage by CRISPR/Cas9: An overview
Martin, F., Sánchez-Hernández, S., Gutiérrez-Guerrero, A., Pinedo-Gomez, J., & Benabdellah, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091507 · Cited by 92
“[29] found off-target sites harboring one-base bulge or up to 13 mismatches between the gRNA and its genomic target.”
BackgroundMethodInfluential
Increased trabecular bone and improved biomechanics in an osteocalcin null rat model created by CRISPR/Cas9 technology
Lambert, L. J., Challa, A. K., Niu, A., Zhou, L., Tucholski, J., Johnson, M. S., Nagy, T. R., Eberhardt, A. W., Estep, P. N., Kesterson, R. A., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025247 · Cited by 94
Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 104
Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments
Kimberland, M. L., Hou, W., Alfonso-Pecchio, A. R., Wilson, S. P., Rao, Y., Zhang, S., & Lu, Q. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.08.007 · Cited by 99
Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Kalter, N., Fuster‐García, C., Silva, A., Ronco-Díaz, V., Roncelli, S., Turchiano, G., Gorodkin, J., Cathomen, T., Benabdellah, K., Lee, C. M., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102636 · Cited by 121

Authors: Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.-J., & Yee, J.-K.
Affiliations: City Of Hope National Medical Center (US)
First Affiliated Hospital Zhejiang University (CN)
Corresponding author: Yee, Jiing-Kuan
ORCID: Wang, Xiaoling
Wu, Xiwei
Wang, Jinhui
Wang, Yingjia
Qiu, Zhaojun
Huang, He
Lin, Ren-Jang
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2015-01-19
Volume: 33
Issue: 2
Pages: 175-178
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.3127
OpenAlex: W2051255304
Cited by: 442
References: 20
Citations by year: 2026: 5 · 2025: 17 · 2024: 18 · 2023: 25 · 2022: 31 · 2021: 38 · 2020: 47 · 2019: 36 · 2018: 46 · 2017: 57 · 2016: 70 · 2015: 52
FWCI: 32.55
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords: off-target cleavage, CRISPR/Cas9, TALEN, integrase-defective lentiviral vectors, genome editing, single guide RNA design, mismatch tolerance
MeSH terms: Genetic Vectors, Humans, Genome, Human, Lentivirus, RNA Editing, Integrases, HEK293 Cells, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks